Arcus Biosciences, Inc(NYSE:RCUS) 
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 a...
Website: http://www.arcusbio.com
Founded: 2015
Full Time Employees: 139
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 7.09
H 7.31
L 6.79
C 6.87
V 1,618,567
10EMA 6.87
20EMA 6.87
60EMA 6.87
120EMA 6.87
250EMA 6.87